/
Metabolic & Endocrine
Overweight
64
Pipeline Programs↗
170
Active Trials↗
80
Companies Involved↗
Overweight is a moderately active landscape with 64 programs across 80 companies. The most active players are Eli Lilly, Novo Nordisk, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 16 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical9
Phase 117
Phase 222
Phase 316
Approved
No programs
Analysis
Modality Breakdown
84%
Small molecule
51 of 61 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 61 classified programs, each share of the total. Modality classified for 97% of 64 pipeline programs.
Analysis
Trial Status
450
clinical trials
Completed240 · 53%
Recruiting79 · 18%
Not yet recruiting58 · 13%
Active, not recruiting29 · 6%
Unknown status17 · 4%
Terminated15 · 3%
Other12 · 3%
Clinical Trials
Trial Activity
450 trials
High-intensity Interval Training Under Hypoxic Versus Normoxic Conditions: Effects on Fat Mass Loss and Gut Microbiota in Adults Aged 50-75 With Overweight or Obesity
Recruiting·LLaboratoire des Adaptations Métaboliques à l'Exercice en conditions Physiologiques et Pathologiques·Preclinical·NCT07796971·32 enrolled
Page 1 of 30
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)